Serious, invasive and often deadly fungal infections treated in the hospital setting are becoming increasingly drug resistant.
SCYNEXIS scientists and innovators who believe in the power of science have developed a new class of antifungal with the potential to battle these difficult to treat diseases.
And we are not stopping there. We continue to work to expand ibrexafungerp’s use with multiple potential future indications. We are evaluating ibrexafungerp in invasive candidiasis, invasive aspergillosis and other fungal infections that are refractory and/or intolerant to other antifungal options. In addition, there are other potential indications for future development. Ibrexafungerp’s potential is incredibly broad, and having the chance to continue advancing it to its maximum potential motivates us every day.
Drug resistance is a critical problem that is present now and will very likely continue growing in years to come. For example, Candida auris causes infections with high mortality and is frequently resistant to azoles and sometimes resistant all antifungal classes approved. Other Candida species have been increasingly growing resistant to many antifungals. Aspergillus strains resistant to azoles have been reported globally, and there is an increased incidence of invasive fungal infections (IFIs) that are typically resistant to current antifungal agents. Mucormycosis is a terribly debilitating fungal infection with a high mortality rate that has shown significant antifungal resistance.
There is an urgent need for new antifungal drugs to adequately manage these challenging and deadly diseases.
As the first glucan synthase inhibitor that can be given orally, ibrexafungerp has the potential to address several of these needs and better position our society to successfully fight the growing threat that fungal infections pose.
Invasive fungal infections kill more than one million people in hospitals each year worldwide.Learn More
Invasive candidiasis is a serious fungal infection caused by various Candida species and occurs most frequently in immunocompromised patients.Learn More
Invasive aspergillosis is a serious fungal infection caused by Aspergillus species that kills more than half of a million people each year worldwide.Learn More
SCYNEXIS is conducting several clinical trials investigating the efficacy of ibrexafungerp against serious and drug-resistant infections.Learn More
SCYNEXIS regularly presents key infectious disease study data at top medical meetings.Learn More
We are working on medicines that have the potential to save lives.Learn More